FDA issues psychedelic drug priority review vouchers

FDA issued national priority vouchers to three companies studying psychedelic-based medicines, fast-tracking approval review following Trump's executive order.

Objective Facts

On Friday April 24, the FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. The companies awarded vouchers are Compass Pathways, the Usona Institute and Transcend Therapeutics. These vouchers were granted under the FDA Commissioners National Priority Voucher pilot program, launched last year as a way to fast-track the review process for certain drugs and biological products seeking approval. According to the Usona Institute, the voucher accelerates FDA review to approximately one to two months, but does not alter scientific or regulatory standards. This latest action by the FDA follows an executive order that President Donald Trump signed Saturday, directing FDA Commissioner Dr. Marty Makary to prioritize psychedelic drugs that have been granted breakthrough therapy status, with Trump's executive order calling for accelerating both research on and access to psychedelic treatments, including a $50 million investment in state governments.

Left-Leaning Perspective

Democratic members of Congress have noted that vouchers have gone to companies that are politically favored by the White House, including those that have agreed to cut prices on their medications. Democratic New Jersey Rep. Frank Pallone Jr. and Independent Vermont Sen. Bernie Sanders expressed "deep concerns" about the CNPV program, noting that it has not received congressional authorization and could "enable corruption by creating a new, lucrative gift for drugmakers and allies politically favored by President Trump". They also cited concerns about CNPV's potential for corruption and misuse as a tool of political favoritism given the limited information on the program, the lack of meaningful transparency about the criteria for qualifying for the CNPV. Critics of the program say it was put in place without seeking input from Congress, and could ultimately undermine trust in the FDA's regulatory process by opening the door for companies to make financial contributions to the administration in an attempt to secure such a voucher. Some worry that it will signal to the public and especially to payers that the evidence behind the approval is weaker, especially for the first drugs on the market in this space that might be detrimental. Former FDA official George Tidmarsh and others have raised concerns about how the program operates without proper congressional oversight. Left-leaning coverage emphasizes the lack of transparency, the unprecedented power given to the FDA commissioner without statutory authority, and the potential for political favoritism. Coverage notably downplays the mental health crisis dimensions that the Trump administration emphasizes, and gives limited attention to the scientific merit of the drugs themselves or veteran advocacy for these treatments.

Right-Leaning Perspective

Reason magazine's libertarian perspective frames Trump's order as both good policy and an encouraging sign of prospects for the movement for psychedelic freedom, hoping to see a similar cascade of support for legalization similar to the dam-breaking that has happened with marijuana legalization in the states. Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, stood behind Trump at the signing ceremony, and Luttrell, along with Reps. Jack Bergman (R-Mich.) and Lou Correa (D-Calif.), leads the Congressional Psychedelics Advancing Therapies Caucus, pushing for "rigorous and urgent clinical research" on psychedelics. President Trump signed an executive order to loosen research restrictions on psychedelic drugs as medicine to treat mental conditions like depression and substance abuse disorder. Trump's announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support, with Joining Trump in the Oval Office his top health officials, conservative podcaster Joe Rogan and Marcus Luttrell, the former Navy SEAL. Right-leaning coverage emphasizes the bipartisan appeal of psychedelics (particularly among veterans), frames the order as addressing genuine unmet mental health needs, and highlights the shift in GOP drug policy away from "war on drugs" rhetoric. What conservative coverage largely omits is sustained scrutiny of the voucher program's governance structure, political favoritism concerns, or the previous FDA rejection of MDMA-assisted therapy for PTSD due to safety and efficacy concerns.

Deep Dive

The FDA's issuance of priority vouchers to three psychedelic drug developers on April 24, 2026, represents the implementation of President Trump's April 18 executive order directing the agency to expedite review of psychedelics that have received "Breakthrough Therapy" designation. The National Priority Voucher program itself was established by the FDA in June 2025, and this marks the first application of the program specifically to psychedelics. The three recipients—Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD)—had all previously received Breakthrough Therapy designation, a designation that itself streamlines FDA interaction. The vouchers promise to compress the normal 10-12 month review timeline into 1-2 months. Critically, Compass had featured in a draft list of CNPV awards last October, but was vetoed by the White House in the eleventh hour, apparently due to concerns over how the action would be viewed by the President's base, illustrating the political dimensions of the program. What each side gets right and what they omit: The left correctly identifies that the CNPV program lacks explicit congressional authorization and operates with limited transparency about selection criteria—a genuine governance concern. The left also notes that previous FDA advisory panels rejected MDMA-assisted therapy in 2024 due to blinding problems, study design flaws, and safety concerns, raising legitimate questions about whether expedited timelines maintain adequate scrutiny. However, left-leaning coverage largely downplays the severity of the mental health crisis (14 million Americans with serious mental illness) and gives minimal attention to veteran advocacy, which is documented as a genuine bipartisan driver of psychedelic research interest. Right-leaning sources correctly emphasize the veteran advocacy angle and the genuine unmet need in treatment-resistant depression and PTSD; they also note that the vouchers do not change the scientific standards FDA applies. However, conservative coverage substantially underemphasizes the governance questions and the fact that late in 2025, the FDA decided against granting accelerated consideration to Compass Pathways' synthetic psilocybin treatment for severe depression before the White House intervened, raising questions about whether clinical merits or political pressure drove the reversal. What to watch: FDA Commissioner Makary stated that the first psychedelic drug could potentially receive approval by end of summer 2026. The immediate question is whether the compressed review timelines reveal any safety or efficacy issues that normal timelines would have caught. Second, ongoing scrutiny from Congress—particularly from Democratic New Jersey Rep. Frank Pallone Jr. and Independent Vermont Sen. Bernie Sanders—will likely focus on whether the program becomes a tool for rewarding politically favored companies. Third, the reimbursement and delivery infrastructure for psychedelic-assisted therapies remains unclear; FDA approval does not automatically mean insurance coverage or access for patients. Finally, the durability of these policies depends on whether Congress ultimately codifies or rejects the CNPV program—as Dan Troy noted, the voucher program, like many of Makary's initiatives, may be short-lived because it isn't codified, with Troy stating "If you live by the press release then you die by the press release. Anything that they're doing now could be wiped out in a moment by the next administration".

FDA issues psychedelic drug priority review vouchers

FDA issued national priority vouchers to three companies studying psychedelic-based medicines, fast-tracking approval review following Trump's executive order.

Apr 24, 2026· Updated Apr 28, 2026

What's Going On

Left says: Democratic lawmakers like Frank Pallone Jr. and Bernie Sanders expressed "deep concerns" that the program could "enable corruption by creating a new, lucrative gift for drugmakers and allies politically favored by President Trump" without congressional authorization.

Right says: Trump's order is both good policy and an encouraging sign of prospects for the movement for psychedelic freedom, with conservative supporters framing it as a sensible approach to addressing treatment-resistant mental illness.

✓ Common Ground

Several voices across the political spectrum acknowledge that easing access to psychedelics for medical use is an issue that has won rare bipartisan support, with both Republicans (notably veterans) and some Democrats supporting research into these compounds for treatment-resistant conditions.

There is broad agreement that psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health treatments in the United States, with some psychedelic drugs once considered fringe being recognized as getting a step closer.

Both the Usona Institute and FDA Commissioner Makary agree that while the vouchers accelerate FDA review, they do not alter scientific or regulatory standards, with Makary emphasizing that as the field moves forward, it is critical that development is grounded in sound science and rigorous clinical evidence.

Commentators across the spectrum acknowledge that the psychedelic community is divided on this latest development, with some believing in the importance of FDA approval of psychedelics and others feeling that it is important for there to be reverence for indigenous ways of relating to these medicines, though it is new and noteworthy that psychedelic therapy is one of the most bipartisan issues in Congress.

CNN - FDA moves to fast-track review of psilocybin and methylone for mental health ABC News - FDA issues vouchers to 3 companies to help fast track review of potential psychedelic medications Harvard Law School Petrie-Flom Center - A New Executive Order on Psychedelics: Q&A with I. Glenn Cohen and Mason Marks The Washington Times - FDA plans ultra-fast review of three psychedelic drugs following Trump directive FDA Official Announcement - FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order

Objective Deep Dive

What each side gets right and what they omit: The left correctly identifies that the CNPV program lacks explicit congressional authorization and operates with limited transparency about selection criteria—a genuine governance concern. The left also notes that previous FDA advisory panels rejected MDMA-assisted therapy in 2024 due to blinding problems, study design flaws, and safety concerns, raising legitimate questions about whether expedited timelines maintain adequate scrutiny. However, left-leaning coverage largely downplays the severity of the mental health crisis (14 million Americans with serious mental illness) and gives minimal attention to veteran advocacy, which is documented as a genuine bipartisan driver of psychedelic research interest. Right-leaning sources correctly emphasize the veteran advocacy angle and the genuine unmet need in treatment-resistant depression and PTSD; they also note that the vouchers do not change the scientific standards FDA applies. However, conservative coverage substantially underemphasizes the governance questions and the fact that late in 2025, the FDA decided against granting accelerated consideration to Compass Pathways' synthetic psilocybin treatment for severe depression before the White House intervened, raising questions about whether clinical merits or political pressure drove the reversal.

What to watch: FDA Commissioner Makary stated that the first psychedelic drug could potentially receive approval by end of summer 2026. The immediate question is whether the compressed review timelines reveal any safety or efficacy issues that normal timelines would have caught. Second, ongoing scrutiny from Congress—particularly from Democratic New Jersey Rep. Frank Pallone Jr. and Independent Vermont Sen. Bernie Sanders—will likely focus on whether the program becomes a tool for rewarding politically favored companies. Third, the reimbursement and delivery infrastructure for psychedelic-assisted therapies remains unclear; FDA approval does not automatically mean insurance coverage or access for patients. Finally, the durability of these policies depends on whether Congress ultimately codifies or rejects the CNPV program—as Dan Troy noted, the voucher program, like many of Makary's initiatives, may be short-lived because it isn't codified, with Troy stating "If you live by the press release then you die by the press release. Anything that they're doing now could be wiped out in a moment by the next administration".

◈ Tone Comparison

Left-leaning sources emphasize procedural irregularities and use language suggesting corruption risk ("enable corruption," "lucrative gift," "shrouded in secrecy"). Right-leaning sources highlight the mental health crisis and use language of breakthrough and liberation ("dramatically accelerate," "save lives," "overcome bureaucratic inertia"). The two sides operate from fundamentally different premises: whether the problem is insufficient FDA process or insufficient patient access.